NASDAQ:AVBP ArriVent BioPharma (AVBP) Stock Price, News & Analysis $20.40 -0.23 (-1.11%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$20.40 0.00 (0.00%) As of 05/23/2025 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About ArriVent BioPharma Stock (NASDAQ:AVBP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ArriVent BioPharma alerts:Sign Up Key Stats Today's Range$19.62▼$20.7050-Day Range$16.30▼$21.3052-Week Range$15.47▼$36.37Volume360,630 shsAverage Volume182,678 shsMarket Capitalization$697.95 millionP/E RatioN/ADividend YieldN/APrice Target$39.29Consensus RatingBuy Company OverviewArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.Read More… ArriVent BioPharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks19th Percentile Overall ScoreAVBP MarketRank™: ArriVent BioPharma scored higher than 19% of companies evaluated by MarketBeat, and ranked 845th out of 918 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingArriVent BioPharma has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageArriVent BioPharma has only been the subject of 4 research reports in the past 90 days.Read more about ArriVent BioPharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for ArriVent BioPharma are expected to decrease in the coming year, from ($2.74) to ($3.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ArriVent BioPharma is -5.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ArriVent BioPharma is -5.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about ArriVent BioPharma's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted27.56% of the float of ArriVent BioPharma has been sold short.Short Interest Ratio / Days to CoverArriVent BioPharma has a short interest ratio ("days to cover") of 26.8, which indicates bearish sentiment.Change versus previous month Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArriVent BioPharma does not currently pay a dividend.Dividend GrowthArriVent BioPharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted27.56% of the float of ArriVent BioPharma has been sold short.Short Interest Ratio / Days to CoverArriVent BioPharma has a short interest ratio ("days to cover") of 26.8, which indicates bearish sentiment.Change versus previous month News and Social Media1.9 / 5News Sentiment0.48 News SentimentArriVent BioPharma has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for ArriVent BioPharma this week, compared to 2 articles on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ArriVent BioPharma insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 9.48% of the stock of ArriVent BioPharma is held by institutions.Read more about ArriVent BioPharma's insider trading history. Receive AVBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ArriVent BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address AVBP Stock News HeadlinesArriVent BioPharma (NASDAQ:AVBP) Downgraded to Strong Sell Rating by Wall Street ZenMay 24 at 1:31 AM | americanbankingnews.comArriVent BioPharma (NASDAQ:AVBP) Earns Buy Rating from Analysts at Jones TradingMay 23 at 2:06 AM | americanbankingnews.comSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.May 25, 2025 | Stansberry Research (Ad)Jones Trading Initiates Coverage of ArriVent BioPharma (AVBP) with Buy RecommendationMay 21, 2025 | msn.comHC Wainwright Issues Pessimistic Forecast for AVBP EarningsMay 18, 2025 | americanbankingnews.comArriVent BioPharma Reports Q1 2025 Financial Results and Highlights Key AchievementsMay 17, 2025 | msn.comHC Wainwright Forecasts Strong Price Appreciation for ArriVent BioPharma (NASDAQ:AVBP) StockMay 17, 2025 | americanbankingnews.comB. Riley Lifts Earnings Estimates for ArriVent BioPharmaMay 16, 2025 | americanbankingnews.comSee More Headlines AVBP Stock Analysis - Frequently Asked Questions How have AVBP shares performed this year? ArriVent BioPharma's stock was trading at $26.64 on January 1st, 2025. Since then, AVBP shares have decreased by 23.4% and is now trading at $20.40. View the best growth stocks for 2025 here. How were ArriVent BioPharma's earnings last quarter? ArriVent BioPharma, Inc. (NASDAQ:AVBP) released its earnings results on Monday, May, 12th. The company reported ($1.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by $1.24. When did ArriVent BioPharma IPO? ArriVent BioPharma (AVBP) raised $175 million in an IPO on Friday, January 26th 2024. The company issued 9,722,222 shares at $18.00 per share. Who are ArriVent BioPharma's major shareholders? Top institutional investors of ArriVent BioPharma include Infinitum Asset Management LLC (6.04%), Vanguard Group Inc. (4.42%), Charles Schwab Investment Management Inc. (0.58%) and Woodline Partners LP (0.43%). Insiders that own company stock include Hillhouse Investment Managemen and Orbimed Advisors Llc. View institutional ownership trends. How do I buy shares of ArriVent BioPharma? Shares of AVBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ArriVent BioPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that ArriVent BioPharma investors own include CRISPR Therapeutics (CRSP), Pure Storage (PSTG), Opendoor Technologies (OPEN), Tesla (TSLA), JPMorgan Chase & Co. (JPM), NVIDIA (NVDA) and Advanced Micro Devices (AMD). Company Calendar Last Earnings5/12/2025Today5/25/2025Next Earnings (Estimated)8/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AVBP Previous SymbolNASDAQ:AVBP CIK1868279 Webwww.arrivent.com Phone628-277-4836FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Stock Price Target$39.29 High Stock Price Target$45.00 Low Stock Price Target$36.00 Potential Upside/Downside+92.6%Consensus RatingBuy Rating Score (0-4)3.14 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($3.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-69,330,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-43.89% Return on Assets-29.67% Debt Debt-to-Equity RatioN/A Current Ratio19.28 Quick Ratio19.28 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($4.79) per share Price / Book-4.26Miscellaneous Outstanding Shares34,213,000Free FloatN/AMarket Cap$697.95 million OptionableN/A Beta1.47 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:AVBP) was last updated on 5/25/2025 by MarketBeat.com Staff From Our PartnersGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ArriVent BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ArriVent BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.